Schaper Benz Wise Investment Counsel Incwi buys $3,864,232 stake in Exactech (EXAC)

Exactech (EXAC) : Schaper Benz Wise Investment Counsel Incwi scooped up 265 additional shares in Exactech during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 170,531 shares of Exactech which is valued at $3,864,232.Exactech makes up approximately 0.71% of Schaper Benz Wise Investment Counsel Incwi’s portfolio.

Exactech opened for trading at $23.55 and hit $24.69 on the upside on Wednesday, eventually ending the session at $23.73, with a gain of 2.64% or 0.61 points. The heightened volatility saw the trading volume jump to 1,18,450 shares. Company has a market cap of $333 M.

Other Hedge Funds, Including , Strs Ohio sold out all of its stake in EXAC during the most recent quarter. The investment firm sold 34,800 shares of EXAC which is valued $788,568. First Quadrant L Pca added EXAC to its portfolio by purchasing 1,000 company shares during the most recent quarter which is valued at $22,660. Kirr Marbach Co In added EXAC to its portfolio by purchasing 12,430 company shares during the most recent quarter which is valued at $281,664. Exactech makes up approx 0.06% of Kirr Marbach Co In’s portfolio.Clean Yield Group reduced its stake in EXAC by selling 27,070 shares or 18.74% in the most recent quarter. The Hedge Fund company now holds 117,397 shares of EXAC which is valued at $2,578,038. Exactech makes up approx 1.14% of Clean Yield Group’s portfolio.Foundry Partners boosted its stake in EXAC in the latest quarter, The investment management firm added 17,321 additional shares and now holds a total of 79,670 shares of Exactech which is valued at $1,605,351. Exactech makes up approx 0.16% of Foundry Partners’s portfolio.

On the company’s financial health, Exactech reported $0.31 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.29. The company had revenue of $65.30 million for the quarter, compared to analysts expectations of $63.54 million. The company’s revenue was up 6.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.29 EPS.

Many Wall Street Analysts have commented on Exactech. Company shares were Upgraded by Robert W. Baird on Apr 13, 2016 to ” Outperform”, Firm has raised the Price Target to $ 26 from a previous price target of $21 .

Exactech Inc. develops manufactures markets distributes and sells orthopedic implant devices related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally. The Company’s operating segments are represented by its major product lines: knee implants hip implants biologics and spine extremity implants and other products. Its other products segment includes miscellaneous sales categories such as surgical instruments held for sale bone cement instrument rental fees shipping charges and other implant product lines. The Company manufactures some components of its knee extremity and hip joint replacement systems at its facility in Gainesville Florida. Its joint replacement products are used by orthopedic surgeons to repair or replace joints that have deteriorated as a result of injury or disease. Its spinal implants are used as an adjunct to the fusion of vertebrae in the treatment of spinal disease and deformity.

Leave a Reply

Exactech - Is it time to Sell?

Top Brokerage Firms are advising their investors on Exactech. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.